LUPIN LIMITED

SAFETY DATA SHEET

Section 1: Identification

Section 1, Identification

Material	**Silodosin Capsules** **4 mg and 8 mg**
Manufacturer	**Lupin Limited** Aurangabad 431 210 India
Distributor	Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202 United States Tel. 001-410-576-2000 Fax. 001-410-576-2221

Section 2: Hazard(s) Identification

Section 2, Hazard(s) identification

Fire and Explosion	Expected to be non-combustible.
Health	• Severe renal impairment (CCr < 30 mL/min) • Severe hepatic impairment (Child-Pugh score ≥ 10) • Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) • Patients with a history of hypersensitivity to silodosin or any of the ingredients of silodosin capsules
Environment	No information is available about the potential of this product to produce adverse environmental effects.

Section 3: Composition/Information on Ingredients

Section 3, Composition/information on ingredients

Ingredients	**CAS**
Silodosin	160970-54-7

Section 4: First-Aid Measures

Section 4, First-aid measures

Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Skin Contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Eye Contact	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment	Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.
OVERDOSAGE	Silodosin was evaluated at doses of up to 48 mg/day in healthy male subjects. The dose-limiting adverse event was postural hypotension. Should overdose of silodosin lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by maintaining the patient in the supine position. If this measure is inadequate, administration of intravenous fluid should be considered. If necessary, vasopressors could be used, and renal function should be monitored and supported as needed. Dialysis is unlikely to be of significant benefit since silodosin is highly (97%) protein bound.

Section 5: Fire-Fighting Measures

Section 5, Fire-fighting measures

Fire and Explosion Hazards	Not determined
Extinguishing Media	Use carbon dioxide, dry chemical, or water spray.
Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.
Hazardous Combustion Products	Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides, hydrogen chloride and other chlorine- and sulfur-containing compounds.

Section 6: Accidental Release Measures

Section 6, Accidental release measures

Personal Precautions	Personnel involved in clean-up should wear appropriate personal protective equipment. Minimize exposure.
Environmental Precautions	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Clean-up Methods	Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Section 7: Handling and Storage

Section 7, Handling and storage

Handling	No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.
Storage	Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature.] Protect from light and moisture. **Keep out of reach of children**

Section 8: Exposure Controls/Personal Protection

Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

Section 9: Physical and Chemical Properties

Section 9, Physical and chemical properties

Physical Form

White, opaque, hard gelatin 4 mg capsules. Cap is imprinted with "LU" in gold. Body is imprinted with "Q71" in gold. 4 mg capsules are supplied in HDPE bottles of:

- 30 capsules (NDC 68180-740-06)
- 90 capsules (NDC 68180-740-09)
- 500 capsules (NDC 68180-740-02)

Bottles of 30 and 90 capsules are supplied with child-resistant closures and bottle of 500 capsules is supplied with non-child-resistant closure.

White, opaque, hard gelatin 8 mg capsules. Cap is imprinted with "LU" in green. Body is imprinted with "Q72" in green. 8 mg capsules are supplied in HDPE bottles of:

- 30 capsules (NDC 68180-741-06)
- 90 capsules (NDC 68180-741-09)
- 500 capsules (NDC 68180-741-02)

Bottles of 30 and 90 capsules are supplied with child-resistant closures and bottle of 500 capsules is supplied with non-child-resistant closure.

Section 10: Stability and Reactivity

Section 10, Stability and reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Section 11, Toxicological information

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 2-year oral carcinogenicity study in rats administered doses up to 150 mg/kg/day [about 8 times the exposure of the maximum recommended human dose (MRHE) based on AUC of silodosin], an increase in thyroid follicular cell tumor incidence was seen in male rats receiving doses of 150 mg/kg/day. Silodosin induced stimulation of thyroid stimulating hormone (TSH) secretion in the male rat as a result of increased metabolism and decreased circulating levels of thyroxine (T4). These changes are believed to produce specific morphological and functional changes in the rat thyroid including hypertrophy, hyperplasia, and neoplasia. Silodosin did not alter TSH or T4 levels in clinical trials and no effects based on thyroid examinations were noted. The relevance to human risk of these thyroid tumors in rats is not known.

In a 2-year oral carcinogenicity study in mice administered doses up to 100 mg/kg/day in males (about nine times the MRHE based on AUC of silodosin) and 400 mg/kg/day in females (about 72 times the MRHE based on AUC), there were no significant tumor findings in male mice. Female mice treated for 2 years with doses of 150mg/kg/day (about 29 times the MRHE based on AUC) or greater had statistically significant increases in the incidence of mammary gland adenoacanthomas and adenocarcinomas. The increased incidence of mammary gland neoplasms in female mice was considered secondary to silodosin-induced hyperprolactinemia measured in the treated mice. Elevated prolactin levels were not observed in clinical trials. The relevance to human risk of prolactin-mediated endocrine tumors in mice is not known. Rats and mice do not produce glucuronidated silodosin, which is present in human serum at approximately four times the level of circulating silodosin and which has similar pharmacological activity to silodosin.

Silodosin produced no evidence of mutagenic or genotoxic potential in the *in vitro* Ames assay, mouse lymphoma assay, unscheduled DNA synthesis assay and the *in vivo* mouse micronucleus assay. A weakly positive response was obtained in two *in vitro* Chinese Hamster Lung (CHL) tests for chromosomal aberration assays at high, cytotoxic concentrations.

Treatment of male rats with silodosin for 15 days resulted in decreased fertility at the high dose of 20 mg/kg/day (about twice the MRHE) which was reversible following a two week recovery period. No effect was

observed at 6 mg/kg/day. The clinical relevance of this finding is not known.

In a fertility study in female rats, the high dose of 20 mg/kg/day (about 1 to 4 times the MRHE) resulted in estrus cycle changes, but no effect on fertility. No effect on the estrus cycle was observed at 6 mg/kg/day.

In a male rat fertility study, sperm viability and count were significantly lower after administration of 600 mg/kg/day (about 65 times the MRHE) for one month. Histopathological examination of infertile males revealed changes in the testes and epididymides at 200 mg/kg/day (about 30 times the MRHE).

Section 12: Ecological Information

Section 12: Ecological Information

No relevant studies identified.

Section 13: Disposal Considerations

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

Section 14: Transport Information

IATA/ICAO - Not Regulated

IATA Proper shipping Name	:	N/A
IATA UN/ID No	:	N/A
IATA Hazard Class	:	N/A
IATA Packaging Group	:	N/A
IATA Label	:	N/A

IMDG - Not Regulated

IMDG Proper shipping Name	:	N/A
IMDG UN/ID No	:	N/A
IMDG Hazard Class	:	N/A
IMDG Flash Point	:	N/A
IMDG Label	:	N/A

DOT - Not Regulated

DOT Proper shipping Name	:	N/A
DOT UN/ID No	:	N/A
DOT Hazard Class	:	N/A
DOT Flash Point	:	N/A
DOT Packing Group	:	N/A
DOT Label	:	N/A

Section 15: Regulatory Information

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.